Modulation of toll-like receptor function has therapeutic potential in autoimmune disease

Bibliography

• Yamashita TS, Khan MA, Kushner I. Genetic analysis of families with multiple cases of rheumatoid arthritis. Dis Markers 1986;4(1-2):113-19
   PubMed Web of Science ®Google Scholar
• Mackay IR. Clustering and commonalities among autoimmune diseases. J Autoimmun 2009;33(3-4):170-7
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84(3):223-43
   PubMedGoogle Scholar
• Luppi P. How immune mechanisms are affected by pregnancy. Vaccine 2003;21(24):3352-7
   PubMed Web of Science ®Google Scholar
• Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010;34(3):J258-65
   PubMed Web of Science ®Google Scholar
• Dantzer R, O'Connor JC, Freund GG, From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9(1):46-56
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009;21(4):317-37
   PubMed Web of Science ®Google Scholar
• Yu M, Wang H, Ding A, HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006;26(2):174-9
   PubMed Web of Science ®Google Scholar
• Termeer C, Benedix F, Sleeman J, Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195(1):99-111
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416(6881):603-7
   PubMed Web of Science ®Google Scholar
• Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001;167(5):2887-94
   PubMed Web of Science ®Google Scholar
• Okamura Y, Watari M, Jerud ES, The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276(13):10229-33
   PubMed Web of Science ®Google Scholar
• Midwood K, Sacre S, Piccinini AM, Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15(7):774-80
   PubMed Web of Science ®Google Scholar
• O'Neill LA. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 2008;29(1):12-20
   PubMed Web of Science ®Google Scholar
• Carty M, Goodbody R, Schroder M, The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006;7(10):1074-81
   PubMed Web of Science ®Google Scholar
• Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006;125(5):943-55
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sato S, Hemmi H, Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301(5633):640-3
   PubMed Web of Science ®Google Scholar
• Oshiumi H, Sasai M, Shida K, TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta. J Biol Chem 2003;278(50):49751-62
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11(5):373-84
   PubMed Web of Science ®Google Scholar
• Park BS, Song DH, Kim HM, The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458(7242):1191-5
   PubMed Web of Science ®Google Scholar
• Taylor KR, Yamasaki K, Radek KA, Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007;282(25):18265-75
   PubMed Web of Science ®Google Scholar
• Bollyky PL, Lord JD, Masewicz SA, Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol 2007;179(2):744-7
   PubMed Web of Science ®Google Scholar
• Asari A, Kanemitsu T, Kurihara H. Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium. J Biol Chem 2010;285(32):24751-8
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003;9(10):1245-50
   PubMed Web of Science ®Google Scholar
• Krause A, Kamradt T, Burmester GR. Potential infectious agents in the induction of arthritides. Curr Opin Rheumatol 1996;8(3):203-9
   PubMedGoogle Scholar
• Munz C, Lunemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev 2009;9(4):246-58
   Google Scholar
• Melief MJ, Hoijer MA, Van Paassen HC, Hazenberg MP. Presence of bacterial flora-derived antigen in synovial tissue macrophages and dendritic cells. Br J Rheumatol 1995;34(12):1112-16
   PubMedGoogle Scholar
• Moen K, Brun JG, Valen M, Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol 2006;24(6):656-63
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Arayssi T, Crane M, Chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. Arthritis Rheum 1999;42(6):1281-4
   PubMed Web of Science ®Google Scholar
• Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005;52(8):2313-22
   PubMed Web of Science ®Google Scholar
• Sacre SM, Andreakos E, Kiriakidis S, The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007;170(2):518-25
   PubMed Web of Science ®Google Scholar
• Brentano F, Schorr O, Gay RE, RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005;52(9):2656-65
   PubMed Web of Science ®Google Scholar
• Itokazu M, Shinozaki M, Ohno T. Quantitative analysis of hyaluronan in the synovial tissues of patients with joint disorders. Clin Rheumatol 1998;17(3):261-2
   PubMed Web of Science ®Google Scholar
• Scott DL, Delamere JP, Walton KW. The distribution of fibronectin in the pannus in rheumatoid arthritis. Br J Exp Pathol 1981;62(4):362-8
   PubMed Web of Science ®Google Scholar
• Yu D, Rumore PM, Liu Q, Steinman CR. Soluble oligonucleosomal complexes in synovial fluid from inflamed joints. Arthritis Rheum 1997;40(4):648-54
   PubMed Web of Science ®Google Scholar
• Taniguchi N, Kawahara K, Yone K, High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003;48(4):971-81
   PubMed Web of Science ®Google Scholar
• Salter DM. Tenascin is increased in cartilage and synovium from arthritic knees. Br J Rheumatol 1993;32(9):780-6
   PubMedGoogle Scholar
• Kyburz D, Rethage J, Seibl R, Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003;48(3):642-50
   PubMed Web of Science ®Google Scholar
• Iwahashi M, Yamamura M, Aita T, Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004;50(5):1457-67
   PubMed Web of Science ®Google Scholar
• Seibl R, Birchler T, Loeliger S, Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003;162(4):1221-7
   PubMed Web of Science ®Google Scholar
• Radstake TR, Roelofs MF, Jenniskens YM, Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004;50(12):3856-65
   PubMed Web of Science ®Google Scholar
• Sacre SM, Lo A, Gregory B, Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J Immunol 2008;181(11):8002-9
   PubMed Web of Science ®Google Scholar
• Ospelt C, Brentano F, Rengel Y, Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008;58(12):3684-92
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee AN, Youn HS. TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin. Arch Pharm Res 2010;33(6):939-45
   PubMed Web of Science ®Google Scholar
• Joosten LA, Koenders MI, Smeets RL, Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003;171(11):6145-53
   PubMed Web of Science ®Google Scholar
• Liu ZQ, Deng GM, Foster S, Tarkowski A. Staphylococcal peptidoglycans induce arthritis. Arthritis Res 2001;3(6):375-80
   PubMedGoogle Scholar
• Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007;56(9):2957-67
   PubMed Web of Science ®Google Scholar
• Kokkola R, Li J, Sundberg E, Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48(7):2052-8
   PubMed Web of Science ®Google Scholar
• Leung BP, Xu D, Culshaw S, A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;173(1):145-50
   PubMed Web of Science ®Google Scholar
• Choe JY, Crain B, Wu SR, Corr M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J Exp Med 2003;197(4):537-42
   PubMed Web of Science ®Google Scholar
• Meng L, Zhu W, Jiang C, Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats. Arthritis Res Ther 2010;12(3):R103
   PubMedGoogle Scholar
• Sacre SM, Drexler SK, Andreakos E, Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis 2007;66(Suppl 3):iii81-6
   PubMedGoogle Scholar
• Sanchez E, Orozco G, Lopez-Nevot MA, Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2004;63(1):54-7
   PubMed Web of Science ®Google Scholar
• Kilding R, Akil M, Till S, A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin Exp Rheumatol 2003;21(3):340-2
   PubMed Web of Science ®Google Scholar
• Kuuliala K, Orpana A, Leirisalo-Repo M, Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. Ann Rheum Dis 2006;65(9):1241-3
   PubMed Web of Science ®Google Scholar
• Sheedy FJ, Marinou I, O'Neill LA, Wilson AG. The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis. Ann Rheum Dis 2008;67(9):1328-31
   PubMed Web of Science ®Google Scholar
• Enevold C, Radstake TR, Coenen MJ, Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis. J Rheumatol 2010;37(5):905-10
   PubMed Web of Science ®Google Scholar
• Etem EO, Elyas H, Ozgocmen S, The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. Rheumatol Int 2010. [Epub ahead of print; doi: 10.1007/s00296-010-1472-8]
   Google Scholar
• Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006;2(9):458-9
   PubMedGoogle Scholar
• Sacre S, Medghalchi M, Gregory B, Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 2010;62(3):683-93
   PubMed Web of Science ®Google Scholar
• Peng G, Wang HY, Peng W, Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007;27(2):334-48
   PubMed Web of Science ®Google Scholar
• Peng G, Guo Z, Kiniwa Y, Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005;309(5739):1380-4
   PubMed Web of Science ®Google Scholar
• Viglianti GA, Lau CM, Hanley TM, Activation of autoreactive B cells by CpG dsDNA. Immunity 2003;19(6):837-47
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8(5):487-96
   PubMed Web of Science ®Google Scholar
• Duramad O, Fearon KL, Chang B, Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005;174(9):5193-200
   PubMed Web of Science ®Google Scholar
• Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum 2004;50(5):1686-9
   PubMed Web of Science ®Google Scholar
• Zeuner RA, Ishii KJ, Lizak MJ, Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum 2002;46(8):2219-24
   PubMed Web of Science ®Google Scholar
• Tabeta K, Hoebe K, Janssen EM, The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006;7(2):156-64
   PubMed Web of Science ®Google Scholar
• Samuels J, Ng YS, Coupillaud C, Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201(10):1659-67
   PubMed Web of Science ®Google Scholar
• Yurasov S, Wardemann H, Hammersen J, Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201(5):703-11
   PubMed Web of Science ®Google Scholar
• Isnardi I, Ng YS, Srdanovic I, IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008;29(5):746-57
   PubMed Web of Science ®Google Scholar
• Sun D, Whitaker JN, Huang Z, Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001;166(12):7579-87
   PubMed Web of Science ®Google Scholar
• Visser L, Jan de Heer H, Boven LA, Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J Immunol 2005;174(2):808-16
   PubMed Web of Science ®Google Scholar
• Hamada T, Driscoll BF, Kies MW, Alvord EC Jr. LPS augments adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Autoimmunity 1989;2(4):275-84
   PubMed Web of Science ®Google Scholar
• Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000;164(11):5683-8
   PubMed Web of Science ®Google Scholar
• Prinz M, Garbe F, Schmidt H, Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006;116(2):456-64
   PubMed Web of Science ®Google Scholar
• Marta M. Toll-like receptors in multiple sclerosis mouse experimental models. Ann NY Acad Sci 2009;1173:458-62
   PubMed Web of Science ®Google Scholar
• Marta M, Andersson A, Isaksson M, Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008;38(2):565-75
   PubMed Web of Science ®Google Scholar
• Touil T, Fitzgerald D, Zhang GX, Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006;177(11):7505-9
   PubMed Web of Science ®Google Scholar
• Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008;118(5):1680-90
   PubMed Web of Science ®Google Scholar
• Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002;61(11):1013-21
   PubMed Web of Science ®Google Scholar
• Andersson A, Covacu R, Sunnemark D, Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008;84(5):1248-55
   PubMed Web of Science ®Google Scholar
• Sloane JA, Batt C, Ma Y, Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci USA 2010;107(25):11555-60
   PubMed Web of Science ®Google Scholar
• Back SA, Tuohy TM, Chen H, Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005;11(9):966-72
   PubMed Web of Science ®Google Scholar
• Bsibsi M, Bajramovic JJ, Vogt MH, The microtubule regulator stathmin is an endogenous protein agonist for TLR3. J Immunol 2010;184(12):6929-37
   PubMed Web of Science ®Google Scholar
• Wu LX, Makela MJ, Roytta M, Salmi A. Effect of viral infection on experimental allergic encephalomyelitis in mice. J Neuroimmunol 1988;18(2):139-53
   PubMed Web of Science ®Google Scholar
• Granieri E, Casetta I, Tola MR, Ferrante P. Multiple sclerosis: infectious hypothesis. Neurol Sci 2001;22(2):179-85
   PubMed Web of Science ®Google Scholar
• Herrmann I, Kellert M, Schmidt H, Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Infect Immun 2006;74(8):4841-8
   PubMed Web of Science ®Google Scholar
• Schrijver IA, van Meurs M, Melief MJ, Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 2001;124(Pt 8):1544-54
   PubMedGoogle Scholar
• Tan EM, Cohen AS, Fries JF, The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25(11):1271-7
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25(4):401-6
   PubMed Web of Science ®Google Scholar
• Niewold TB, Hua J, Lehman TJ, High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8(6):492-502
   PubMed Web of Science ®Google Scholar
• Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24(2):178-81
   PubMed Web of Science ®Google Scholar
• Musone SL, Taylor KE, Lu TT, Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;40(9):1062-4
   PubMed Web of Science ®Google Scholar
• Tavares RM, Turer EE, Liu CL, The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010;33(2):181-91
   PubMed Web of Science ®Google Scholar
• Armstrong DL, Reiff A, Myones BL, Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun 2009;10(5):446-56
   PubMed Web of Science ®Google Scholar
• Castiblanco J, Varela DC, Castano-Rodriguez N, TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008;8(5):541-4
   PubMed Web of Science ®Google Scholar
• Akahoshi M, Nakashima H, Sadanaga A, Promoter polymorphisms in the IRF3 gene confer protection against systemic lupus erythematosus. Lupus 2008;17(6):568-74
   PubMed Web of Science ®Google Scholar
• Jacob CO, Zhu J, Armstrong DL, Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009;106(15):6256-61
   PubMed Web of Science ®Google Scholar
• Herrmann M, Voll RE, Zoller OM, Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41(7):1241-50
   PubMed Web of Science ®Google Scholar
• Savarese E, Steinberg C, Pawar RD, Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008;58(4):1107-15
   PubMed Web of Science ®Google Scholar
• Ehlers M, Fukuyama H, McGaha TL, TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203(3):553-61
   PubMed Web of Science ®Google Scholar
• Vollmer J, Tluk S, Schmitz C, Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005;202(11):1575-85
   PubMed Web of Science ®Google Scholar
• Khan N, Summers CW, Helbert MR, Arkwright PD. Effects of age, gender, and immunosuppressive agents on in vivo toll-like receptor pathway responses. Hum Immunol 2010;71(4):372-6
   PubMed Web of Science ®Google Scholar
• Pisitkun P, Deane JA, Difilippantonio MJ, Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006;312(5780):1669-72
   PubMed Web of Science ®Google Scholar
• Subramanian S, Tus K, Li QZ, A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006;103(26):9970-5
   PubMed Web of Science ®Google Scholar
• Shen N, Fu Q, Deng Y, Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci USA 2010;107(36):15838-43
   PubMed Web of Science ®Google Scholar
• Lau CM, Broughton C, Tabor AS, RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202(9):1171-7
   PubMed Web of Science ®Google Scholar
• Christensen SR, Kashgarian M, Alexopoulou L, Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005;202(2):321-31
   PubMed Web of Science ®Google Scholar
• Lartigue A, Colliou N, Calbo S, Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol 2009;183(10):6207-16
   PubMed Web of Science ®Google Scholar
• Guiducci C, Gong M, Xu Z, TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010;465(7300):937-41
   PubMed Web of Science ®Google Scholar
• Summers SA, Hoi A, Steinmetz OM, TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun 2010;35(4):291-8
   Google Scholar
• Nickerson KM, Christensen SR, Shupe J, TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010;184(4):1840-8
   PubMed Web of Science ®Google Scholar
• Jin O, Kavikondala S, Mok MY, Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2010;12(4):R137
   PubMedGoogle Scholar
• Richardson B, Scheinbart L, Strahler J, Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990;33(11):1665-73
   PubMed Web of Science ®Google Scholar
• Lunec J, Herbert K, Blount S, 8-Hydroxydeoxyguanosine. A marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett 1994;348(2):131-8
   PubMed Web of Science ®Google Scholar
• Urbonaviciute V, Furnrohr BG, Weber C, Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007;81(1):67-74
   PubMed Web of Science ®Google Scholar
• Hornung V, Rothenfusser S, Britsch S, Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168(9):4531-7
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding IB, Wagner M, Hornung V, Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005;174(7):4043-50
   PubMed Web of Science ®Google Scholar
• Migita K, Miyashita T, Maeda Y, Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007;34(3):493-500
   PubMed Web of Science ®Google Scholar
• Komatsuda A, Wakui H, Iwamoto K, Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008;152(3):482-7
   PubMed Web of Science ®Google Scholar
• Papadimitraki ED, Choulaki C, Koutala E, Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006;54(11):3601-11
   PubMed Web of Science ®Google Scholar
• Papadimitraki ED, Tzardi M, Bertsias G, Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus 2009;18(9):831-5
   PubMed Web of Science ®Google Scholar
• Ciferska H, Horak P, Konttinen YT, Expression of nucleic acid binding Toll-like receptors in control, lupus and transplanted kidneys–a preliminary pilot study. Lupus 2008;17(6):580-5
   PubMed Web of Science ®Google Scholar
• Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010;53(6):2345-53
   PubMed Web of Science ®Google Scholar
• Schopf L, Savinainen A, Anderson K, IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum 2006;54(10):3163-73
   PubMed Web of Science ®Google Scholar
• Izmailova ES, Paz N, Alencar H, Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis Rheum 2007;56(1):117-28
   PubMed Web of Science ®Google Scholar
• Hammaker D, Sweeney S, Firestein GS. Signal transduction networks in rheumatoid arthritis. Annals of the rheumatic diseases 2003;62(Suppl 2):ii86-9
   PubMedGoogle Scholar
• Kishore N, Sommers C, Mathialagan S, A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem 2003;278(35):32861-71
   PubMed Web of Science ®Google Scholar
• von Bernuth H, Picard C, Jin Z, Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008;321(5889):691-6
   PubMed Web of Science ®Google Scholar
• Iyer S, Kontoyiannis D, Chevrier D, Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000;275(22):17051-7
   PubMed Web of Science ®Google Scholar
• DeVry CG, Valdez M, Gao L, RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 2004;152(1-2):33-43
   PubMed Web of Science ®Google Scholar
• Travis S, Yap LM, Hawkey C, RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005;11(8):713-19
   PubMed Web of Science ®Google Scholar
• Loiarro M, Capolunghi F, Fanto N, Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007;82(4):801-10
   PubMed Web of Science ®Google Scholar
• Capolunghi F, Rosado MM, Cascioli S, Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology (Oxford) 2010. [Epub ahead of print. doi: 10.1093/rheumatology/keq226]
   Google Scholar
• Youn HS, Lee JY, Fitzgerald KA, Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005;175(5):3339-46
   PubMed Web of Science ®Google Scholar
• Youn HS, Lee JY, Saitoh SI, Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by (-)-epigallocatechin-3-gallate, a polyphenol component of green tea. Biochem Pharmacol 2006;72(7):850-9
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee MY, Son BS, Youn HS. TBK1-targeted suppression of TRIF-dependent signaling pathway of Toll-like receptors by 6-shogaol, an active component of ginger. Biosci Biotechnol Biochem 2009;73(7):1474-8
   PubMed Web of Science ®Google Scholar
• Guahk GH, Ha SK, Jung HS, Zingiber officinale protects HaCaT cells and C57BL/6 mice from ultraviolet B-induced inflammation. J Med Food 2010;13(3):673-80
   PubMed Web of Science ®Google Scholar
• Rossi JF, Negrier S, James ND, A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010;103(8):1154-62
   Google Scholar
• Vanags D, Williams B, Johnson B, Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006;368(9538):855-63
   PubMed Web of Science ®Google Scholar
• Broadley SA, Vanags D, Williams B, Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult Scler 2009;15(3):329-36
   PubMed Web of Science ®Google Scholar
• Kumar MV, Nagineni CN, Chin MS, Innate immunity in the retina: toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol 2004;153(1-2):7-15
   PubMed Web of Science ®Google Scholar
• Elass E, Aubry L, Masson M, Mycobacterial lipomannan induces matrix metalloproteinase-9 expression in human macrophagic cells through a Toll-like receptor 1 (TLR1)/TLR2- and CD14-dependent mechanism. Infect Immun 2005;73(10):7064-8
   PubMed Web of Science ®Google Scholar
• Erridge C, Spickett CM, Webb DJ. Non-enterobacterial endotoxins stimulate human coronary artery but not venous endothelial cell activation via Toll-like receptor 2. Cardiovasc Res 2007;73(1):181-9
   PubMed Web of Science ®Google Scholar
• Ungaro R, Fukata M, Hsu D, A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009;296(6):G1167-79
   PubMed Web of Science ®Google Scholar
• Roger T, Froidevaux C, Le Roy D, Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 2009;106(7):2348-52
   PubMed Web of Science ®Google Scholar
• Ranjith-Kumar CT, Duffy KE, Jordan JL, Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3. Mol Cell Biol 2008;28(14):4507-19
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Gregorio J, Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202(8):1131-9
   PubMed Web of Science ®Google Scholar
• Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum 2005;52(2):651-8
   PubMed Web of Science ®Google Scholar
• Latz E, Verma A, Visintin A, Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007;8(7):772-9
   PubMed Web of Science ®Google Scholar
• Boivin N, Sergerie Y, Rivest S, Boivin G. Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis. J Infect Dis 2008;198(5):664-72
   PubMed Web of Science ®Google Scholar
• Dorner T. Therapy: hydroxychloroquine in SLE: old drug, new perspectives. Nat Rev Rheumatol 2010;6(1):10-11
   PubMed Web of Science ®Google Scholar
• Honda K, Yanai H, Negishi H, IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434(7034):772-7
   PubMed Web of Science ®Google Scholar
• Haas T, Schmitz F, Heit A, Wagner H. Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells. Immunology 2009;126(2):290-8
   PubMed Web of Science ®Google Scholar
• Tidswell M, Tillis W, Larosa SP, Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010;38(1):72-83
   PubMed Web of Science ®Google Scholar
• Nakamura M, Shimizu Y, Sato Y, Toll-like receptor 4 signal transduction inhibitor, M62812, suppresses endothelial cell and leukocyte activation and prevents lethal septic shock in mice. Eur J Pharmacol 2007;569(3):237-43
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355(10):1018-28
   PubMed Web of Science ®Google Scholar
• Dzopalic T, Dragicevic A, Vasilijic S, Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability. Int Immunopharmacol 2010;10(11):1428-33
   Google Scholar
• Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009;10(11):1200-7
   PubMed Web of Science ®Google Scholar
• Casrouge A, Zhang SY, Eidenschenk C, Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006;314(5797):308-12
   PubMed Web of Science ®Google Scholar
• Schett G, Redlich K, Xu Q, Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. J Clin Invest 1998;102(2):302-11
   PubMed Web of Science ®Google Scholar
• Fort MM, Mozaffarian A, Stover AG, A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005;174(10):6416-23
   PubMed Web of Science ®Google Scholar
• Legat A, Thomas S, Hermand P, CD14-independent responses induced by a synthetic lipid A mimetic. Eur J Immunol 2010;40(3):797-802
   PubMed Web of Science ®Google Scholar